BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Evorpacept readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Evorpacept\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04643002-3357@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Evorpacept: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Evorpacept\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Novel Agents in RRMM - Master Protocol\nEstimated prima
 ry completion: 13 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/evorpacept#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007559-3357@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Evorpacept: Phase 2 readout est. (NCT07007559)
DESCRIPTION:Evorpacept\, phase 2\, HER2-Positive Breast Cancer.\nStudy: ASP
 EN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemot
 herapy in Metastatic HER2-Positive Breast Cancer\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 evorpacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07007559
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-3357@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Evorpacept: Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Evorpacept\, phase 1/2.\nStudy: ALX148\, Rituximab and Lenalido
 mide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymph
 oma\nEstimated primary completion: 21 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/evorpacept#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05025800
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-3357@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Evorpacept: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Evorpacept\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: P
 RE-ISPY Phase I/II Oncology Platform Program\nEstimated primary completion
 : 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 vorpacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05868226
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
